Eradivir Revenue and Competitors

Eradivir’s founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules. These therapies all function by attaching various payloads to ligands, which bind with high specificity to diseased cells. Examples of approved molecules include a radiotherapy drug for prostate cancer and an intraoperative imaging agent for lung and ovarian cancers. Several others are currently in clinical trials (e.g., treatments for cancer, malaria, and sickle cell anemia). Eradivir was founded in March 2020 to advance a promising application of this platform in combating multiple disease states, initially focusing on influenza and other respiratory infections.